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Pre-formulation and systematic 
evaluation of amino acid assisted 
permeability of insulin across  
in vitro buccal cell layers
Affiong Iyire, Maryam Alayedi & Afzal R. Mohammed
The aim of this work was to investigate alternative safe and effective permeation enhancers for buccal 
peptide delivery. Basic amino acids improved insulin solubility in water while 200 and 400 μg/mL  
lysine significantly increased insulin solubility in HBSS. Permeability data showed a significant 
improvement in insulin permeation especially for 10 μg/mL of lysine (p < 0.05) and 10 μg/mL histidine 
(p < 0.001), 100 μg/mL of glutamic acid (p < 0.05) and 200 μg/mL of glutamic acid and aspartic acid 
(p < 0.001) without affecting cell integrity; in contrast to sodium deoxycholate which enhanced insulin 
permeability but was toxic to the cells. It was hypothesized that both amino acids and insulin were 
ionised at buccal cavity pH and able to form stable ion pairs which penetrated the cells as one entity; 
while possibly triggering amino acid nutrient transporters on cell surfaces. Evidence of these transport 
mechanisms was seen with reduction of insulin transport at suboptimal temperatures as well as with 
basal-to-apical vectoral transport, and confocal imaging of transcellular insulin transport. These results 
obtained for insulin are the first indication of a possible amino acid mediated transport of insulin via 
formation of insulin-amino acid neutral complexes by the ion pairing mechanism.
The primary driving factor for investigating non-invasive routes for delivering biologicals is built on reducing/
removing the need for single/multiple daily injections, which puts a major strain on patient compliance and 
desired therapeutic outcome1. On the other hand, mucosal delivery of biologicals has been reported to be less 
effective than parenteral delivery for various reasons including limited mucosal permeation, as well as absorption 
site metabolism2. However, high vascularisation and presence of fewer proteolytic enzymes in the buccal mucosa 
compared to the gastrointestinal tract (GIT) mucosa promotes buccal delivery as a potential site for protein and 
peptide delivery. Limitations of buccal delivery of proteins include: large molecular weight and hydrophilicity 
leading to low diffusivity; instability, fast metabolism, adsorption, aggregation and possible immunogenicity2. 
Thus factors affecting peptide drug absorption including structure (molecular weight/size, conformation, 
stereo-specificity, immunogenicity and electrostatic charge); physicochemical properties (solubility, hydrophilic-
ity/partition coefficient, aggregation, self-aggregation and hydrogen bonding); buccal mucosal properties (struc-
ture and biochemistry); biological environment (enzyme sensitivity and intracellular metabolism) and available 
transport mechanisms have to be considered during buccal formulation development.
Strategies such as chemical modification by derivatisation, or prodrug approaches may enhance peptide 
stability and lipophilicity, and may prevent degradation by proteolytic enzymes at the mucosal surface2. Other 
strategies that result in the formation of non-covalent complexes between the protein and hydrophilic moieties 
have been reported to impart slight reversible unfolding to the peptide molecule, leading to enhanced protein 
flexibility and lipophilicity1,3. This increases passive transcellular diffusion and enhances protein permeability, 
and is the principle behind the use of ion pairs to enhance drug permeation. An ion pair is formed when a pair of 
oppositely charged (counter) ions are held together without the formation of a covalent bond; forming a neutral 
molecule with higher lipophilicity, that can partition into the cell membrane easier than the parent compound4. 
Most ion pairing agents such as inorganic surfactants and co-solvents require high volumes, resulting in high 
toxicity/allergenicity and have limited applications in pharmaceutical preparations4–6. Recently, the use of amino 
acids as ion pairs to enhance solubility/permeability of small molecules has been investigated as a biodegradable, 
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low toxicity/irritant and high stability alternative6. Moreover, the availability of amino acid transport across cells 
may enhance facilitated transport of drug-amino acid complexes (after ion pair formation), leading to enhanced 
permeation7. Various studies have investigated the use of amino acids as ion pairs to improve solubility/perme-
ability of small molecules4,8–11. However the use of amino acids as ion pairs to enhance solubility/permeability 
has not been extensively reported for proteins and macromolecules. Usually, with small molecules, molar ratios 
of the counter ion are used in excess5, but molar ratios cannot be employed for macromolecules because these 
would require minute quantities of amino acids which in turn would produce negligible improvements. Also, the 
large size, amphiphilic nature, and presence of multiple ionisable sites on proteins further complicate the expected 
results in vitro.
In order to establish the role of ion pairs in the formulation of biologicals, the proposed work is built on 
insulin as a model compound. Insulin has high solubility (depending on solution pH) and low permeability, 
mostly due to its large molecular weight, low lipophilicity and degradation in the presence of proteases12. The 
insulin monomer consists of six basic groups and six acidic groups which become ionised depending on solution 
pH13. The current work was based on two hypotheses. Firstly, that ionised insulin molecules could form ion pairs 
with opposite charges provided by basic and acidic amino acids to form an insulin-amino acid neutral complex 
with enhanced lipophilicity, which could then permeate the buccal membrane via transcellular passive diffusion. 
Secondly, that complexation of insulin with amino acids could possibly trigger alternate facilitated transport 
mechanism of insulin-amino acid complex across buccal membranes. Thus the aim of this work was to investigate 
the ion pairing effect of basic and acidic amino acids on the solubility, permeability, mechanism and the transport 
route of insulin across TR146 buccal cell layers.
Results and Discussion
Insulin solubility in water. There is a lack of consensus on solubility of insulin in water as different authors 
have either reported it as soluble/hydrophilic15 or insoluble/hydrophobic16. However, the solubility of insulin 
is determined by the pH of the solution, and its closeness to the isoelectric point of insulin17. Kramer et al.18 
described protein solubility as a thermodynamic parameter defined as “the concentration of protein in a saturated 
solution that is in equilibrium with a solid phase, either crystalline or amorphous, under a given set of conditions”. 
This solubility depends primarily on intrinsic factors such as characteristics of its constituent amino acids, as well 
as extrinsic factors such as temperature, pH, ionic strength and solvent additives18. Our results show that insulin 
remained only slightly soluble in deionised water (< 3 μ g/mL) (pH 6.64). Similar results were obtained by Lens17 
who measured insulin solubility at pH 6.0. Landreh19 also reported low insulin solubility at pH 5–6. The insulin 
monomer consists of six basic groups (two N-terminal amino groups, two histidine, one lysine and one arginine) 
and six acidic groups (two C-terminal carboxylates and four glutamates)13. Therefore at pH values around its 
isoelectric point of 5.35, charges on the monomer balance out providing a neutral molecule, rendering insulin 
practically insoluble in water4,14. At acidic pH, the acidic groups on insulin become protonated, and the resulting 
charge on the molecule is provided by the basic groups (NH3+), thus insulin has a positive charge in acidic media. 
However, in basic media, the acidic groups lose their protons and the charge on the monomer is provided by the 
acidic groups (COO−), giving insulin a negative charge in basic media. At the near neutral pH of deionised water 
(pH 6.6), the charges on the acidic and basic groups of insulin balance out to give a neutral molecule with no net 
charge, resulting in low solubility of the protein4,14.
Insulin solubility in HBSS.  Insulin solubility in HBSS was determined because it was expected that at pH 7.4 
(more than 2 units above the isoelectric point of insulin) the protein would be soluble thereby overcoming pre-
cipitation20. HBSS also enabled the circumvention of the potential toxicity related to solubilising insulin in 0.01N 
HCl prior to permeation experiments as reported by other authors21,22. For HBSS solubility studies, a range of 
ionisable amino acids was utilised, their physicochemical properties are presented in Supplementary Table S1. As 
expected, insulin was highly soluble in HBSS (pH 7.4) as reported by Lens17. In the presence of basic amino acids 
(Supplementary Fig. S1), arginine and lysine were able to increase solution pH from 7.4 to 9.2 at concentrations 
above 100 μ g/mL, while histidine caused no change in solution pH (pKa of the histidine side chain (6.04) causes it 
to act neutral or slightly basic at neutral pH and thus could not affect solution pH). However, only lysine was able 
to significantly enhance insulin solubility in HBSS from concentrations 200 μ g/mL and above. This disparity in 
solubility enhancement for the basic amino acids is related to the isoelectric points of these amino acids and the 
basicity of their ionisable side chains. Elshaer et al.7 also reported higher solubility enhancement for indometha-
cin by lysine than arginine due to the self-association that exists between lysine and the drug. In the presence of 
the acidic amino acids (Supplementary Fig. S2), a reduction in solution pH was observed at amino acid concen-
trations above 200 μ g/mL (due to the buffering capacity of HBSS); and a subsequent reduction in solubility was 
observed at these concentration (formation of a cloudy solution on visual examination) which were close to the 
isoelectric point of insulin23.
The effect of amino acids on insulin solubility was compared to that of sodium deoxycholate (Na deoxy-
cholate), a hydrophobic bile salt that has been widely studied as a permeation enhancer. This is a surfactant 
that enhances permeability of biological membranes by dissolution of membrane lipids thereby interfering with 
membrane fluidity and integrity24–27. As a detergent, Na deoxycholate acts as an amphiphile and possesses both 
polar and non-polar properties and is able to enhance the emulsification of insoluble substances by reducing 
interfacial surface tension28. Na deoxycholate (pKa 6.58) had no effect on solution pH even at the highest concen-
trations. However, a significant reduction in insulin solubility was observed at 100 μ g/mL Na deoxycholate. This 
was because the bile salt has been shown to confer a concentration - dependent hydrophobicity on proteins like 
insulin, thereby enhancing its lipophilicity, which would reduce aqueous solubility29.
Therefore, it can be concluded that the amino groups of the basic amino acids and the carboxyl groups of the 
acidic amino acids have the capacity for ionisation, and affect insulin solubility due to the ease of formation of 
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ion pairs and soluble complexes in the presence of counter ions furnished by ionisable sites on the insulin moiety. 
This effect was dependent on the resultant system pH, pKa of the amino acids and the differences between these 
values and the isoelectric points of both insulin and the amino acids14.
Insulin permeability across TR146 cell layers.  Ion pairs can be formed in the presence of oppositely 
charged ions in solution. Polypeptides such as insulin with multiple potentially ionisable regions depending on 
the amino acid sequence and system pH, have the potential of forming ion pairs with amino acid side chains, 
to increase lipophilicity and thus may enhance permeability30. TR146 cells were grown on transwell inserts for 
28–29 days before use for permeability experiments. Integrity of the stratified layers was monitored using TEER 
as shown in Supplementary Fig. S3. TEER results showed the formation of a stable stratified layer between days 
28 to 29 which were used for experiments, as reported by other authors21.
The permeation of insulin across TR146 cell layers was tested in the absence/presence of increasing concentra-
tions of the three basic (arginine, lysine and histidine), two acidic (aspartic acid and glutamic acid) amino acids 
and Na deoxycholate. Amino acids with ionisable side chains were chosen to facilitate ion-pairing with insulin 
via the counter ion mechanism; insulin is amphiphilic and can behave as an acid or a base depending on solution 
pH. Na deoxycholate was chosen as a model surfactant that has been well established in literature as a permeation 
enhancer, to determine if similar or better enhancement effects could be obtained from amino acids, without the 
toxicity issues presented by surfactants. The maximum amount of insulin that permeated the cells in the absence 
of amino acids (control) was 4.07 ± 0.82% after 4 hours.
Basic Amino Acids. Insulin permeation results in the presence of basic amino acids are expatiated in Figs 1,2 and 
3 for arginine, lysine and histidine respectively. The coefficient of apparent permeability of insulin through the 
actual cell layers, without the interference of the membrane Pcell, was calculated using equation 5 and results are 
presented in Supplementary Table S2. Amino acid concentrations that showed significant enhancement in insulin 
permeability include 10, 100 and 200 μ g/mL for lysine (Fig. 2b) and 10 μ g/mL for histidine (Fig. 3b). Arginine was 
not able to significantly enhance insulin permeability above that of the control (Fig. 1b). This observation could 
Figure 1. Permeation of human insulin across TR146 buccal cell layers in the presence of increasing 
arginine concentrations. (a) Percentage of insulin permeated in the presence of various concentrations of 
arginine. (b) Comparing the percent enhancement of insulin permeability through TR146 cell layers in the 
presence of various concentrations of arginine and solution pH. (c) Comparing the solubility at 25 °C and 
permeability of insulin through TR146 cells layers, of insulin in the presence of various concentrations of 
arginine.
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be accounted for by the inability of arginine to significantly alter the solubility (and therefore the dissociation), 
of insulin above the control (Supplementary Fig. S1). Arginine has a basic side chain with pKa 12.48 and at lower 
arginine concentrations of 10–100 μ g/mL (solution pH 7.4–7.8), both insulin and arginine would be expected 
to be ionised and able to form stable unionised ion pairs that would enhance insulin permeability11. Significant 
increase in permeability at these lower concentrations of arginine was not observed possibly due to the presence 
of a limited concentration of ionised arginine molecules to pair with the ionised insulin moieties. However, as 
arginine concentration increased, solution pH increased steadily to a maximum of 9.36 at 600 μ g/mL arginine. 
As this pH is close to the isoelectric point of arginine (10.71), it is possible that although insulin molecules were 
ionised, less ionisation of the arginine molecule occurred, with the presence of fewer counter ions available to 
form neutral insulin-arginine moieties, and the final result of insignificant difference in insulin permeation was 
observed4,9.
From Supplementary Fig. S1, insulin solubility (and therefore insulin ionisation) was observed to signifi-
cantly increase for lysine concentrations ≥ 200 μ g/mL, with resultant increase in pH from 7 to 9. Thus, at pH of 7 
(100 μ g/mL lysine), both lysine and insulin molecules would be ionised, the potential for formation of insulin-lysine 
neutral molecules would be enhanced with a further increase in permeability. As discussed for arginine earlier, 
concentrations of lysine above 200 μ g/mL, pH of the solution moved closer to the isoelectric point of lysine (9.74), 
causing a reduction in lysine ionisation, a fall in the concentration of lysine counter ions available for neutral com-
plex formation with insulin, and a resultant fall in permeability as shown in Fig. 2c. However at 50 μ g/mL lysine, a 
fall in insulin permeability was observed, probably due to the low concentrations of lysine available for complexa-
tion with ionised insulin moieties. Surprisingly, 10 μ g/mL lysine significantly enhanced insulin permeability above 
the control. This observation could be related to the high ionisation of lysine and insulin at pH 7. On the other 
hand, insulin permeability could have been facilitated in the presence of lysine through amino acid membrane 
transporters which could have been saturated at higher concentrations11,31. Insulin permeability results with lysine 
as permeation enhancer reinforced the fact that for permeation enhancement to occur in dynamic systems, a strin-
gent balance between ionised and non-ionised species must be maintained4,9,11. 100–200 μ g/mL was found to be 
the ideal concentration of lysine to enhance solubility and permeability of insulin in vitro.
Figure 2. Permeation of human insulin across TR146 buccal cell layers in the presence of increasing lysine 
concentrations. (a) Percentage of insulin permeated in the presence of various concentrations of lysine.  
(b) Comparing the percent enhancement of insulin permeability through TR146 cell layers in the presence of 
various concentrations of lysine and solution pH. (c) Comparing the solubility at 25 °C and permeability of 
insulin through TR146 cells layers, of insulin in the presence of various concentrations of lysine.
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All concentrations of histidine above 10 μ g/mL showed no significant effect on insulin permeation. As 
highlighted in Supplementary Fig. S1, increasing histidine concentration above 10 μ g/mL had no significant 
effect on insulin solubility in HBSS, with no change in solution pH at all concentrations tested. It was expected 
that histidine and insulin were ionised at this pH, the availability of counter ions facilitated the formation of 
insulin-histidine neutral complexes that could enhance insulin permeability significantly. Figure 3c compares the 
solubility and permeability of insulin at different concentrations of histidine. From here, it can be seen that no 
advantage was produced for both insulin solubility and permeability when histidine concentration was increased 
above 10 μ g/mL. Similar to results obtained from lysine, 10 μ g/mL histidine was able to produce the optimal 
balance between ionised and non-ionised insulin molecules in solution, as well as possibly effectively triggering 
peptide transport proteins to enhance the permeation of insulin across TR146 buccal cells.
Acidic amino acids. Insulin permeation results in the presence of acidic amino acids are expatiated in Figs 4 and 
5 for glutamic acid and aspartic acid respectively. Amino acid concentrations that showed significant enhance-
ment in insulin permeability include 10, 100 & 200 μ g/mL for glutamic acid (Fig. 4b) and 10 & 200 μ g/mL for 
aspartic acid (Fig. 5b). These observations for glutamic acid can be directly related to the solubility profile pre-
sented in Supplementary Fig. S2 and were expected based on the discussions in sections above. No significant 
difference in insulin solubility and solution pH was observed with increasing glutamic acid concentrations up to 
200 μ g/mL, however, at 400 μ g/mL, insulin solubility reduced drastically with a solution pH of 6.09 at 600 μ g/mL 
(Fig. 4b). As these pH values were close to the isoelectric point of insulin, less insulin was found in solution with 
outright precipitation of insulin expected at 600 μ g/mL. Thus no insulin was observed to permeate the cells at this 
high glutamic acid concentration (Fig. 4c); because only the soluble form of a drug is available to permeate cells 
and be absorbed into the bloodstream4,9,32.
Increasing aspartic acid concentration above 400 μ g/mL did not enhance insulin absorption. Similar to results 
observed for glutamic acid, increasing aspartic acid concentrations to 200 μ g/mL did not significantly change 
the solubility of insulin or solution pH (Supplementary Fig. S2). However for concentrations above 200 μ g/mL, 
insulin permeability drastically declined, with a significant drop in solution pH. However, at all concentrations 
tested, insulin solubility was higher for aspartic acid than for glutamic acid. This could be attributed to the fact 
that the pKa of aspartic acid is lower than that of glutamic acid, and thus there was a larger difference in pKa 
between insulin and aspartic acid, than insulin and glutamic acid. Elshaer et al.7 suggested that for candidates to 
Figure 3. Permeation of human insulin across TR146 buccal cell layers in the presence of increasing 
histidine concentrations. (a) Percentage of insulin permeated in the presence of various concentrations of 
histidine. (b) Comparing the percent enhancement of insulin permeability through TR146 cell layers in the 
presence of various concentrations of histidine and solution pH. (c) Comparing the solubility at 25 °C and 
permeability of insulin through TR146 cells layers, of insulin in the presence of various concentrations of 
arginine.
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sufficiently ionise to produce counter ions that could form non-ionised complexes that enhance permeability, the 
difference in pKa should be up to 3 units.
Safe and effective amino acids as permeation enhancers. Since an aim of this study was to discover effective and 
safe penetration enhancers for insulin through buccal cells, transepithelial electrical resistance (TEER) of the cell 
layers (results reported in Supplementary Table S3) and the MTT assay (results represented in Supplementary 
Fig. S4) were conducted to assess the toxicity of amino acids to the cells, to determine if any observed perme-
ation enhancement was due to destruction of cell layers or increase in cellular toxicity. The TEER results for 
arginine exhibited no significant reduction in TEER values across all concentrations of arginine used. Thus, cell 
layer integrity can be said to have been maintained throughout the 4 hours of the permeability experiment11,21,33. 
Elshaer11 reported similar findings where high concentrations of arginine did not significantly affect the TEER 
measurements before and after permeability studies using Caco-2 cells. This was an expected result since MTT 
results revealed a reduction in cell viability for concentrations greater than 500 μ g/mL. Thus, although arginine 
was a safe enhancer, it did not significantly enhance the permeation of insulin through TR146 cells34. These MTT 
results for arginine were in conflict with findings reported by Xue et al.21, where 10–50 μ g/mL arginine solutions 
were found to be toxic to TR146 cells using the MTT assay. This conflict could be explained on the basis that in 
the current study, TR146 cells were exposed to amino acids for 4 hours (duration of a permeability study35) while 
in the earlier study, exposure times ranged from 24–48 hours. However, because the TR146 cells used for perme-
ability studies formed multiple layers of stratified squamous epithelial cells, while MTT assays were carried out 
on single cells in active exponential growth phase, low toxicity is to be expected from the permeability studies21. 
TEER results presented in Supplementary Table S3 revealed that 100 μ g/mL lysine significantly reduced TEER 
values post permeability assay, thus the enhancement recorded for this concentration could have been produced 
by leakage through disrupted cellular layers21. MTT assay results (see Supplementary Fig. S4) further revealed 
a significant concentration dependent decrease in TR146 cell viability with lysine concentrations ≥ 100 μ g/mL 
which could affect cell integrity34. Furthermore, above 100 μ g/mL lysine, pH values increased beyond physiolog-
ically accepted pH (Fig. 2b). TEER results for histidine (Supplementary Table S3) showed that only 100 μ g/mL 
histidine significantly disrupted cellular integrity, and results from MTT assay (Supplementary Fig. S4) revealed 
that histidine was non-toxic to TR146 cells even at the highest concentration (800 μ g/mL) tested. Therefore for 
the basic amino acids, although 10, 100 and 200 μ g/mL lysine and 10 μ g/mL histidine were effective as permea-
tion enhancers for insulin, only 10 μ g/mL of each amino acid were both effective and non-toxic to TR146 cells 
(Supplementary Fig. S5) and were chosen as optimal concentrations that effectively enhanced permeation of 
Figure 4. Permeation of human insulin across TR146 buccal cell layers in the presence of increasing 
glutamic acid concentrations. (a) Percentage of insulin permeated in the presence of various concentrations 
of glutamic acid. (b) Comparing the percent enhancement of insulin permeability through TR146 cell layers in 
the presence of various concentrations of glutamic acid and solution pH. (c) Comparing the solubility at 25 °C 
and permeability of insulin through TR146 cells layers, of insulin in the presence of various concentrations of 
glutamic acid.
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insulin without affecting cell viability or causing membrane disruption36–38. 10 μ g/mL histidine showed signifi-
cantly higher permeation enhancement than 10 μ g/mL lysine.
TEER results from Supplementary Table S3 showed no significant reduction in TEER values at all concentra-
tions of glutamic acid tested, and only 600 μ g/mL aspartic acid significantly reduced TEER values. While MTT 
assay results (Supplementary Fig. S4) revealed toxicity of cells only at 800 μ g/mL for both glutamic and aspartic 
acids respectively. However these concentrations were not employed in permeability studies. Thus, glutamic and 
aspartic acids was found to be safe and non-toxic to cells across all tested concentrations. Thus, the enhancement 
in insulin permeability by 10, 100 & 200 μ g/mL glutamic acid and 10 & 200 μ g/mL aspartic acid could be attrib-
uted solely to the amino acid facilitation of permeation through the formation of neutral ion pairs with insulin, 
or through the use of membrane peptide transporters, rather than disruption of cell layers or reduced cellu-
lar integrity9,11. Therefore for the acidic amino acids 10, 100 and 200 μ g/mL glutamic acid and 10 & 200 μ g/mL 
aspartic acid were able to effectively and safely enhance insulin permeation without any toxicity to TR146 cells 
(Supplementary Fig. S6).
Sodium deoxycholate. Sodium deoxycholate (SDC) is a bile acid salt with pKa 6.58 (Supplementary Table S1) 
which has been widely investigated for its role in enhancing permeation of drugs across cell membranes39–42. In 
this study, the effectiveness and safety of the amino acids as permeation enhancers were compared against that 
obtained with sodium deoxycholate, to verify if amino acids could serve as less toxic and safer alternative permea-
tion enhancers for insulin than bile salts. From Fig. 6b, 200, 400 and 600 μ g/mL sodium deoxycholate were able to 
significantly enhance insulin permeability. The high enhancement with SDC was an expected finding based on the 
ability of surfactants to fluidise the lipid membranes of the cells and impact on their integrity and barrier forming 
properties39. This effect was seen with TEER results, where a significant linear drop in TEER values signifying a 
reduction in cell layer integrity was recorded at concentrations of SDC > 100 μ g/mL (Supplementary Table S2). 
Cell viability results (Supplementary Fig. S4) further confirmed increased toxicity of cells exposed to 100 μ g/mL 
SDC and above. Xue et al.21 reported no significant change in TEER results in the presence of 10 and 50 μ g/mL 
Na deoxycholate, however 10–50 μ g/mL reduced the viability of TR146 cells after 24–48 hour exposure. Because 
the increase in insulin permeability afforded by SDC showed a linear trend (Fig. 6c), while that of the amino 
acids showed a somewhat “zig-zag trend”, it is possible that for the amino acids, a further mechanism (such as 
Figure 5. Permeation of human insulin across TR146 buccal cell layers in the presence of increasing 
aspartic acid concentrations. (a) Percentage of insulin permeated in the presence of various concentrations 
of aspartic acid. (b) Comparing the percent enhancement of insulin permeability through TR146 cell layers 
in the presence of various concentrations of arginine and solution pH. (c) Comparing the solubility at 25 °C 
and permeability of insulin through TR146 cells layers, of insulin in the presence of various concentrations of 
aspartic acid.
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triggering of amino acid/peptide transporters) outside disruption of cell membranes, came into play. Surfactants 
such as SDC enhance drug permeation paracellularly by binding to calcium ions or disruption of hemi desmo-
somes between cells which might enhance both paracellular and transcellular transport43,44. Thus, because of the 
toxicity exhibited by SDC, none of the tested concentrations yielded effective and safe permeation enhancement.
Supplementary Fig. S7 compares the concentrations of enhancers that effectively and safely improved insulin 
permeation across TR146 cell layers in vivo. It can be noted that apart from arginine which showed no significant 
improvement in the coefficient of apparent permeability through the cell layers (Pcell), at 10 μ g/mL all amino 
acids were safe and effective; SDC was safe but ineffective. At high concentrations of 200 μ g/mL, the acidic amino 
acids were both safe and effective while lysine and SDC were effective but unsafe; and at 100 μ g/mL, only glutamic 
acid was safe and effective; lysine was effective but unsafe, while SDC was safe but ineffective. Thus, we have been 
able to demonstrate that acidic and basic amino acids act as effective penetration enhancers which circumvent the 
toxicity issues related with the use of surfactants such as SDC.
Route of insulin transport. After identifying safe and effective amino acid permeation enhancers for 
insulin, the next priority was to determine the route of insulin transport (whether paracellular or trascellular) 
across the buccal cell layers. In order to test our first hypothesis that formation of neutral insulin-amino acid ion 
pairs with higher lipophilicity would enhance transcellular insulin transport by passive diffusion, FITC-labelled 
insulin (6 μ g/mL) was transported for 4 hours across TR146 cells grown on transwell inserts and analysed by 
confocal microscopy. Results revealed localisation of FITC-insulin molecules in the cell cytoplasm (not para-
cellularly), both in the presence and absence of amino acids and bile salts (Fig. 7). Supplementary Fig. S8 shows 
DAPI-stained images confirming that FITC-insulin localisation occurred close to the nucleus. These findings 
were in contrast to investigations for FITC-labelled dextran 4 kDa as a marker for paracellular transport via 
TR146 cell layers; which traversed the buccal cells via the paracellular route with no localisation at all in the 
nucleus or cytoplasm (Supplementary Fig. S9). These results confirmed our hypothesis that insulin transport 
did not occur paracellularly but was through the transcellular route. The paracellular route has been reported to 
transport small hydrophilic molecules (≤ 300 Da) by passive diffusion. The absence of paracellular transport for 
insulin was expected due to its large molecular weight (5,800 Da) and the fact that the intercellular spaces of the 
buccal cavity are highly lipophilic due to the extrusion of the lipid content of the membrane coating granules that 
occur in the upper two-thirds of the buccal epithelium into the intercellular spaces, thereby inhibiting buccal 
Figure 6. Permeation of human insulin across TR146 buccal cell layers in the presence of increasing 
sodium deoxycholate concentrations. (a) Percentage of insulin permeated in the presence of various 
concentrations of sodium deoxycholate. (b) Comparing the percent enhancement of insulin permeability 
through TR146 cell layers in the presence of various concentrations of aspartic acid and solution pH. 
(c) Comparing the solubility at 25 °C and permeability of insulin through TR146 cells layers, of insulin in the 
presence of various concentrations of sodium deoxycholate.
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paracellular transport39,40. The transcellular transport observed in the absence of amino acids (control) indicates 
that insulin transport possibly occurred via insulin receptors. Similar findings were recorded by Thompson et al.45 
who investigated the transport of FITC-insulin across Caco-2 cell lines (model for small intestines) and reported 
localisation of FITC-insulin in the cell cytoplasm after 30 minutes exposure at 3 μ g/mL. This uptake of insulin was 
reported to be mediated by interactions with insulin receptors45. Xu46 reported that confocal microscopic imag-
ing of FITC-labelled insulin showed that insulin could be transported via both the transcellular and paracellular 
routes in rabbit buccal mucosa.
Mechanism of insulin transport through TR146 cell culture model.  Upon confirming that insulin 
traversed the buccal cell layers via the transcellular and not the paracellular route, we needed to test our second 
hypothesis that this transport was by active transporter facilitated mechanisms. Glutamic acid was chosen as a 
representative amino acid since it showed enhanced permeation and overall safety over the widest range of con-
centrations tested. Similarly, Sauberlich47 reported that of all the 20 amino acids fed in excess of recommended 
doses to weanling rats, L-glutamic acid showed the least toxicity expressed as inhibition of growth, and showed 
the least absorption into the plasma.
To confirm the presence of active transport, the concentration of insulin was kept constant at 1 mg/mL while 
glutamic acid concentration was varied at 0, 100, 200 and 400 μ g/mL. Transport experiments were carried out 
in a cold room at 9 °C. Results depicted in Fig. 8a revealed a significant reduction in insulin permeation at 9 °C 
compared with 36 °C. Cellular activities cease at suboptimal temperatures, therefore a fall in permeation at lower 
temperatures would depict a cessation of active transport.
Furthermore, at 9 °C the amount of insulin permeated decreased with increasing amino acid concentration. 
These results point to the presence of active transport of insulin-glutamic acid neutral complexes formed by 
ion-pairing, possibly via amino acid/peptide transporters in the cell membranes48. Membrane transporters are 
membrane bound proteins that selectively facilitate the transport of substances across biological membranes49. 
Inactivation of enzymatic activity at suboptimal temperatures results in reduced function of these transporters, 
thereby inhibiting insulin permeation across the cell layer. Furthermore, as transporter activity had already been 
Figure 7. Confocal microscopic images showing transport pathway of FITC-labelled insulin through 
TR146 buccal cell layers in the presence of amino acid concentrations that effectively enhanced insulin 
permeability. Insulin observed to traverse transcellularly with localisation in the nucleus. Control (A), Arg  
50 μ g/ml (B), Asp10 μ g/ml (C), Asp 200 μ g/ml (D), Glu 10 μ g/ml (E), Glu 100 μ g/ml (F), Glu 200 μ g/ml (G), Hist 
10 μ g/ml (H), Lys 10 μ g/ml (I), Lys 100 μ g/ml (J), Lys 200 μ g/ml (K), Na 200 μ g/ml (L).
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compromised by the low temperature, increasing amino acid concentrations above 100 μ g/mL caused a further 
reduction and ultimate cessation of insulin transportation probably through early saturation of the transporters11. 
It is possible that the low transport recorded at 400 μ g/mL glutamic acid could be related to the low solubility of 
insulin at this concentration (Supplementary Fig. S2), however this concentration showed insulin permeation at 
36 °C (Fig. 4c), thereby suggesting that the change was due to saturation of the transporter proteins11,50.
To further establish the presence of active transport in this system, glutamic acid concentration was main-
tained at 200 μ g/mL while insulin concentration was varied at 250, 500, 1000 and 1500 μ g/mL (Fig. 8b). It was 
observed that increasing insulin concentrations above 500 μ g/mL showed no significant increase in permeation. 
Biochemical reports on the buccal epithelium reveal the extrusion of lipid components of the epithelium into the 
paracellular spaces, thereby increasing its lipophilicity and causing an added permeation barrier37. Thus, passive 
paracellular diffusion would not be expected for a macro molecule such as insulin (5,800 Da) since this route 
favours the transport of hydrophilic molecules ≤ 300 Da48. Passive diffusion relies on the concentration gradient 
between the extracellular and intracellular compartments, while active transport can occur against a concentra-
tion gradient, therefore, no increase in permeation would be observed with increasing drug concentration if the 
molecule was solely transported actively48. The rate of transport in passive diffusion is governed by Fick’s law and 
is therefore directly dependent on the initial concentration; with active transport, this relationship is only relevant 
at low concentrations, and with increasing concentrations, carrier saturation occurs and no increase in uptake 
is observed with increasing concentrations48. Thus results from Fig. 8b, confirm the presence of active transcel-
lular transport for insulin. We further investigated vectoral transport of insulin across the cell layers (Fig. 8b). 
Reversal of transport direction from apical-basolateral, to basolateral-apical revealed a concentration depend-
ent decrease in insulin permeation, with no permeation recorded at 250 and 500 μ g/mL insulin. According to 
Biopharmaceutical Classification System guidelines, to confirm the presence of passive transport in vitro, there 
should be a lack of dependence on initial concentration and directional transport; since the concentration of 
nutrient transporter proteins are higher at the apical surface than at the basolateral surface.48. Thus these results 
further point to the presence of active transport for insulin. Artusson et al.50 agreed that highly potent hydro-
philic compounds such as peptide antigens, with similar structures as food nutrients could be transported across 
cell layers by a combination of active facilitated transport as well as passive transport. However, these results 
obtained for insulin are the first indication of a possible amino acid mediated transport of insulin via formation 
of insulin-amino acid neutral complexes by the ion pairing mechanism.
Conclusion
The results of these studies demonstrated a “bell-shaped” impact on insulin permeability upon increasing the 
concentration of amino acid counter ions, and suggest that the concentration of the counter ion requires optimi-
sation to provide a balance between insulin dissociation and permeation. Interestingly, investigating the mech-
anism and route of insulin permeation using increasing concentrations of insulin at suboptimal temperatures, 
Figure 8. To investigate active insulin transport in the presence of amino acids. (a) Insulin concentration 
was fixed at 1mg/ml while glutamic acid concentration was varied, and permeation experiments carried out at 
9 °C for 4 hours. (b) Vectoral transport of increasing concentrations of insulin with glutamic acid concentration 
was fixed at 200 μ g/ml. Temperature and concentration dependent fall in insulin permeation at suboptimal 
temperatures, and lower basal-to-apical insulin transport, confirm the presence of active transport of insulin.
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reversed transport direction and confocal microscopy revealed that insulin was transported by passive and active 
transcellular processes provided by the presence of insulin receptors and amino acid nutrient transporters on the 
cell membrane. Therefore, amino acids were established as safer, effective and novel penetration enhancers, than 
the commonly used surfactant Na deoxycholate, for insulin using the ion-pairing mechanism.
Materials and Methods
Materials. TR146 cell line was purchased from Public Health England, UK. Human recombinant insulin, 
L-arginine (non-animal source, cell culture tested), L-lysine (≥ 97%), L-histidine (≥ Reagent Plus 99%), 
L-glutamic acid (minimum 99% TLC), L-aspartic acid (99%), sodium deoxycholate, thiazolyl blue tetrazolium 
bromide (methylthiazolydiphenyl-tetrazolium bromide; ≥ 97%; enzymatic), dimethyl sulfoxide (DMSO) and tri-
fluoroacetic acid were purchased from Sigma-Aldrich, UK. Hanks balanced salt solution (HBSS), Fetal bovine 
saline (FBS) were obtained from Gibco Lab., UK. Acetoniltrile and absolute ethanol were purchased from Fisher 
scientific, UK. Hank’s balanced salt solution (HBSS), fetal bovine serum (FBS), Hams F-12 nutrient mix and 
trypsin-EDTA were obtained from Gibco® Lab., UK. Gentamicin and penicillin/ streptomycin were obtained 
from Bio Sera, UK. Acetoniltrile and absolute ethanol were purchased from Fisher scientific, UK. 6 well plates, 6 
well polycarbonate transwell inserts and 12 well polyester transwell inserts were purchased from Appletonwoods, 
UK. All the chemicals and reagents were used as obtained. All water used was double-distilled and autoclaved.
Methods. High Performance Liquid Chromatography (HPLC) Assay. Quantitative analysis of insulin in 
solution was achieved by gradient RP-HPLC adapted from Sarmento51. A Waters HPLC system (Alliance) with 
gradient pump and UV/fluorescent detector was used, employing a reversed phase RP-C18 analytical column 
(Phenomenex 110A, 150 × 4.6 mm, 5 μ m). The mobile phase consisted of solution A: 0.1% v/v TFA in water and 
solution B: absolute acetonitrile both filtered under vacuum and sonicated prior to use. A gentle gradient was 
run from 74:26 to 67:33 compositions of A:B over 3 mins, and then maintained at 67:33 for 4 mins. Pump flow 
rate was 1 mL/min, with sample injection volume of 10 μ L and UV detector wavelength of 214 nm. Column and 
samples were maintained at room temperature. The maximum wavelength of absorption of insulin had been 
pre-determined using a Unicam UV-visible spectrophotometer. The method was validated using ICH guidelines.
Insulin solubility in water and HBSS. Solubility studies were carried out at 25 °C by adding excess amounts of 
insulin in 5 ml of deionised water containing 4, 27 or 50 μ g/mL concentrations of arginine and glutamic acid 
respectively. pH of the solutions was measured using a pHenomenal pH meter (VWR-USA). The solutions were 
then allowed to stir on a multi IKA magnetic stirrer overnight7,52. After standing for 2 hours, the supernatant was 
filtered through 0.45 μ m filters, and insulin content quantified by HPLC. Similar experiments were carried out 
using 10, 50, 100, 200, & 400 μ g/mL concentrations of basic (arginine, lysine & histidine) and acidic (glutamic 
acid & aspartic acid) amino acids and Na deoxycholate, using HBSS in place of deionised water. This was because 
in vitro permeability studies would be carried out in HBSS. Solutions without amino acids were used as control.
TR146 Cell Culture Procedures. TR146 cells were maintained in 75 cm3 T-flasks in Ham’s F-12 cell culture media 
fortified with 10% FBS, 2 mM glutamine, 100 IU penicillin/streptomycin, 10 μ g gentamicin; and incubated at 
37 °C, 5% CO2 and 95% air. Media change occurred every 2–3 days and at 90% confluence, cells were passaged 
using 5 mL trypsin-EDTA solution, and seeded unto 12 well transwell inserts at a density of 24,000 cells/cm2. 
Transepithelial electrical resistance (TEER) was used to monitor cellular layer integrity 30 minutes after each 
media change11. Passage numbers 30–39 were used for these experiments.
Trans-epithelium electric resistance (TEER). The ohmic resistance (resistance to current flow via the paracellular 
pathway) of cells grown on transwell inserts was measured using an EVOM volt ohmmeter with chopstick elec-
trodes. The electrodes were placed erect, such that the longer arm just touched the fluid in the basolateral cham-
ber, while the shorter arm barely touched the apical membrane. TEER which reveals the integrity of the cellular 
layers was calculated using the equation below, and reported as mean ± standard deviation of triple readings from 
replicate transwells (n = 9).
= − ⁎TEER R R A( ) (1)insert with cells insert without cells
where R is the measured resistance and A is the cross-sectional area of the cells.
Cytotoxicity testing via MTT assay. The methylthiazolydiphenyl-tetrazolium bromide (MTT) assay was used to 
assess the cytotoxicity of the enhancers on TR146 cells in their exponential growth phase. Cells were seeded unto 
96 well plates at a density of 24,000 cells/cm2 and incubated for 24 hours. The media was removed and 200 μ L of 
increasing concentrations (25, 50, 100, 200, 400 and 800 μ g/mL) of each enhancer in HBSS was added to each well 
in replicates of 12 per concentration. Cells were incubated for 4 hours (the duration of permeability experiments) 
after which 20 μ L MTT solution (5 mg/mL in PBS) was added to each well and incubated for a further 4 hours. 
Finally, wells were emptied and solutions replaced with 100 μ L dimethyl sulfoxide (DMSO) and left to shake at 
140 rpm and 37 °C for 30 minutes. The absorbance was read at 490 nm using a Multiskan spectrum plate reader 
(Thermoscientific, UK). The relative enzyme reactivity and therefore cell viability was calculated from:
=
−
−
×Cell viability OD OD
OD OD
100
1 (2)
1 2
3 2
OD1, OD2 and OD3 are the optical densities of wells with cells and enhancer solution, blank wells without cells or 
enhancer solution, and wells with cells but no enhancer solution respectively.
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In vitro transbuccal permeation studies. Permeability studies were conducted as described by Nielsen and 
Rassing53 at 36 °C and 140 rpm in an orbital plate shaker. Test solutions containing 1000 μ g/mL insulin dissolved 
in HBSS in the presence of increasing concentrations (0,10, 50, 100, 200, 400 and 600 μ g/mL) of amino acids as 
well as sodium deoxycholate were prepared and stirred until a clear solution was observed, and pH of solutions 
measured. Cells on transwell inserts were rinsed twice with HBSS (37 °C) by adding 0.5 mL and 1.5 mL respec-
tively to the apical and basolateral chambers respectively. After incubation for 30 mins, TEER readings were taken 
in triplicate per insert. The basolateral chamber was then replaced with fresh HBSS and the apical chamber with 
0.5 mL test solution. Immediately, 100 μ L of test solution was withdrawn from the apical and basolateral cham-
bers at time 0. Basolateral sampling of 700 μ L was done every 30 mins for 4 hours with immediate replacement 
with pre-warmed HBSS. At the end of the experiment, 100 μ L of apical solution was taken. Test solutions without 
permeation enhancers were used as control21,54,55. After 4 hours, cells were rinsed twice with 0.5 mL HBSS and 
equilibrated for 30 minutes after which TEER values were recorded. All samples were made up to 700 μ L where 
necessary, using HBSS, and analysed for insulin content by HPLC, and resultant data used to calculate the appar-
ent coefficient of permeability through the insert with cells (Papp), the cell-free apparent permeability coefficient 
(Pins), the cell apparent permeability coefficient (Pcell), the percent enhancement ratio (%ER) and the recovery %.
= × ⁎P
dQ
dt A C
1
(3)app o
= × ⁎P
dQ
dt A C
1
(4)ins o
= +
P P P
1 1 1
(5)app cell ins
= ×ER
P
P
% 100
1 (6)
cell enhancer
cell control
( )
( )
=
+
×Recovery
X X
X
% 100
1 (7)
apical basolateral
o
dQ/dt is the rate of insulin transport at steady state in μ g/s, A is the cross sectional area of cells in cm2, CO is the 
initial apical solution concentration in μ g/mL, Xapical is the quantity of insulin remaining in the apical chamber 
after 4 hours, Xbasolateral is the cumulative amount of insulin sampled from the basolateral chamber after 4 hours 
and Xo is the initial quantity of insulin in the apical chamber at the start of the experiment21,55,56.
Insulin stability after permeation was monitored by HPLC for changes in retention time and/or presence of 
multiple peaks on the HPLC chromatogram.
Route of insulin transport. Solutions containing FITC-labelled insulin (0.6 mg/mL in HBSS) along with con-
centrations of enhancers that effectively enhanced insulin permeability, were incubated with TR146 cells; as with 
the transport experiments57. TEER values in HBSS were measured before and after the experiment. After 4 hours, 
transwell inserts with cells were washed three times with warm HBSS and fixed with 4% paraformaldehyde (PFA) 
in PBS for 10 minutes, and cells were rinsed four times with PBS. Inserts were placed on microscope slides and the 
membrane carefully cut out using a scalpel. Two drops of DAPI (4′ 6′ -diamidino-2-phenylindole) in Vectashield 
(Vector Laboratories,UK) were used to mount the specimen which was immediately covered with a microscope 
cover slip and allowed to air dry for 10 minutes. Samples were then imaged using a Leica laser confocal scanning 
microscope (Germany) at 10x (dry) and 40x (oil) magnifications.
Mechanism of insulin transport. To investigate the presence of passive transport, permeability studies described 
above were carried out at 36 °C (optimised temperature for TR146 cells) using a single concentration of glutamic 
acid (200 μ g/mL) with increasing concentrations of insulin (250, 500, 1000 and 1500 μ g/mL) and all permeability 
indices calculated. While to investigate the presence of active amino acid-facilitated transport of insulin, permea-
bility studies were repeated at suboptimal temperatures (9 °C) with 1000 μ g/mL insulin in the presence of increas-
ing concentrations of glutamic acid (100, 200 &, 400 μ g/mL). Transwells were maintained at 9 °C for 1 hour prior 
to commencing studies to ensure a cessation of enzymatic activity, and the resulting insulin transport analysed by 
HPLC. Cellular activities cease at suboptimal temperatures, therefore a fall in permeation at lower temperatures 
would depict a cessation of active transport.
Statistical Analysis. All data was presented as mean ± standard deviation and analysed using One-way ANOVA 
and Turkey-Kramar multiple comparison post-test from Graphpad Prism version 6.07 (California, USA). Level 
of significance was quoted as p < 0.05 (probability values of 95%).
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